Aquestive Therapeutics Stock Price, News & Analysis (NASDAQ:AQST) $2.47 +0.08 (+3.35%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$2.35▼$2.6750-Day Range$1.30▼$2.4752-Week Range$0.72▼$2.69Volume1.07 million shsAverage Volume381,794 shsMarket Capitalization$164.92 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Aquestive Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside142.9% Upside$6.00 Price TargetShort InterestHealthy2.88% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.88Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.07) to ($0.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.86 out of 5 starsMedical Sector679th out of 952 stocksPharmaceutical Preparations Industry318th out of 434 stocks 3.5 Analyst's Opinion Consensus RatingAquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Aquestive Therapeutics has a forecasted upside of 142.9% from its current price of $2.47.Amount of Analyst CoverageAquestive Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.88% of the outstanding shares of Aquestive Therapeutics have been sold short.Short Interest Ratio / Days to CoverAquestive Therapeutics has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Aquestive Therapeutics has recently decreased by 1.54%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAquestive Therapeutics does not currently pay a dividend.Dividend GrowthAquestive Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AQST. Previous Next 3.3 News and Social Media Coverage News SentimentAquestive Therapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aquestive Therapeutics this week, compared to 2 articles on an average week.Search Interest6 people have searched for AQST on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows14 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 367% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aquestive Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.39% of the stock of Aquestive Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 30.91% of the stock of Aquestive Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aquestive Therapeutics are expected to decrease in the coming year, from ($0.07) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aquestive Therapeutics is -9.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aquestive Therapeutics is -9.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Aquestive Therapeutics Stock (NASDAQ:AQST)Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.Read More AQST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AQST Stock News HeadlinesNovember 29, 2023 | finance.yahoo.comAquestive Therapeutics (AQST) Just Flashed Golden Cross Signal: Do You Buy?November 28, 2023 | finance.yahoo.comBest Momentum Stocks to Buy for November 28thDecember 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 27, 2023 | finance.yahoo.comAquestive Therapeutics (AQST) Is Up 2.98% in One Week: What You Should KnowNovember 21, 2023 | finance.yahoo.comThose who invested in Aquestive Therapeutics (NASDAQ:AQST) a year ago are up 90%November 16, 2023 | finance.yahoo.comAquestive Therapeutics (AQST) Upgraded to Strong Buy: Here's What You Should KnowNovember 13, 2023 | morningstar.comAquestive Therapeutics Inc AQSTNovember 10, 2023 | finance.yahoo.comAquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual MeetingDecember 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 9, 2023 | benzinga.comAquestive Therapeutics Stock (NASDAQ:AQST), Analyst Ratings, Price Targets, PredictionsNovember 8, 2023 | markets.businessinsider.comPositive Outlook for Aquestive Therapeutics: Early Trial Start, Surpassing Financial Expectations and Successful Debt RefinancingNovember 8, 2023 | finance.yahoo.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Q3 2023 Earnings Call TranscriptNovember 6, 2023 | finance.yahoo.comAquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 6, 2023 | finance.yahoo.comAquestive Therapeutics Inc (AQST) Reports 25% Year-Over-Year Growth in Year-to-Date RevenueNovember 3, 2023 | msn.comCanaccord believes Rani restructuring will help speed developmentNovember 3, 2023 | benzinga.comPreview: Aquestive Therapeutics's EarningsNovember 2, 2023 | finance.yahoo.comAquestive Therapeutics Completes $45 Million Debt RefinancingNovember 1, 2023 | finance.yahoo.comAquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to KnowOctober 31, 2023 | finance.yahoo.comAquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ETOctober 24, 2023 | msn.comAquestive Therapeutics (AQST) Beats Stock Market Upswing: What Investors Need to KnowOctober 11, 2023 | msn.comWedbush Reiterates Aquestive Therapeutics (AQST) Outperform RecommendationOctober 10, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Aquestive Therapeutics (AQST), Guardant Health (GH)October 9, 2023 | finance.yahoo.comAquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's WhyOctober 9, 2023 | markets.businessinsider.comFDA Approvals and Strong Business Performance Reinforce Buy Rating for Aquestive TherapeuticsOctober 4, 2023 | finance.yahoo.comAquestive Therapeutics (AQST) Stock Moves -0.71%: What You Should KnowSeptember 22, 2023 | msn.comARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In BothSeptember 21, 2023 | markets.businessinsider.comWedbush Sticks to Its Buy Rating for Aquestive Therapeutics (AQST)See More Headlines Receive AQST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AQST CUSIPN/A CIK1398733 Webwww.aquestive.com Phone(908) 941-1900FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$8.00 Low Stock Price Target$4.00 Potential Upside/Downside+142.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,410,000.00 Net Margins-25.20% Pretax Margin-24.90% Return on EquityN/A Return on Assets-20.63% Debt Debt-to-Equity RatioN/A Current Ratio1.76 Quick Ratio1.47 Sales & Book Value Annual Sales$47.68 million Price / Sales3.46 Cash FlowN/A Price / Cash FlowN/A Book Value($2.19) per share Price / Book-1.13Miscellaneous Outstanding Shares66,770,000Free Float61,165,000Market Cap$164.92 million OptionableNot Optionable Beta2.73 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Daniel Barber (Age 47)CEO, President & Director Comp: $925.35kMr. Alexander Mark Schobel (Age 64)Chief Innovation & Technology Officer Comp: $672.69kMs. Lori J. Braender BSBA (Age 67)Esq., J.D., Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $678.76kMr. A. Ernest Toth Jr. (Age 64)Chief Financial Officer Comp: $679.9kMs. Cassie Jung (Age 44)Senior Vice President of Operations Mr. Peter E. Boyd (Age 57)Senior Vice President of IT, HR & Communications Mr. Kenneth W. Marshall (Age 64)Chief Commercial Officer Dr. Gary H. Slatko M.D. (Age 66)MBA, Chief Medical Officer Dr. Stephen Wargacki (Age 45)Senior VP of Research & Development Dr. Carl N. Kraus M.D. (Age 53)Chief Medical Officer More ExecutivesKey CompetitorsNuvectis PharmaNASDAQ:NVCTPraxis Precision MedicinesNASDAQ:PRAXEsperion TherapeuticsNASDAQ:ESPRSeres TherapeuticsNASDAQ:MCRBOptiNoseNASDAQ:OPTNView All CompetitorsInstitutional OwnershipWalleye Capital LLCSold 248,310 shares on 11/21/2023Ownership: 0.233%Armistice Capital LLCBought 3,642,000 shares on 11/15/2023Ownership: 7.189%GSA Capital Partners LLPBought 86,902 shares on 11/15/2023Ownership: 0.151%Acadian Asset Management LLCBought 388,017 shares on 11/13/2023Ownership: 0.824%Connor Clark & Lunn Investment Management Ltd.Bought 30,898 shares on 11/13/2023Ownership: 0.371%View All Institutional Transactions AQST Stock Analysis - Frequently Asked Questions Should I buy or sell Aquestive Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AQST shares. View AQST analyst ratings or view top-rated stocks. What is Aquestive Therapeutics' stock price target for 2024? 3 Wall Street research analysts have issued 1 year price objectives for Aquestive Therapeutics' stock. Their AQST share price targets range from $4.00 to $8.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 142.9% from the stock's current price. View analysts price targets for AQST or view top-rated stocks among Wall Street analysts. How have AQST shares performed in 2023? Aquestive Therapeutics' stock was trading at $0.9021 at the beginning of 2023. Since then, AQST stock has increased by 173.8% and is now trading at $2.47. View the best growth stocks for 2023 here. When is Aquestive Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024. View our AQST earnings forecast. How were Aquestive Therapeutics' earnings last quarter? Aquestive Therapeutics, Inc. (NASDAQ:AQST) announced its quarterly earnings results on Monday, November, 6th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.08. The company had revenue of $13 million for the quarter, compared to the consensus estimate of $11.33 million. What other stocks do shareholders of Aquestive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Organigram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB). When did Aquestive Therapeutics IPO? (AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers. Who are Aquestive Therapeutics' major shareholders? Aquestive Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (7.19%), Acadian Asset Management LLC (0.82%), Connor Clark & Lunn Investment Management Ltd. (0.37%), Walleye Capital LLC (0.23%), GSA Capital Partners LLP (0.15%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, Lori J Braender and Peter E Boyd. View institutional ownership trends. How do I buy shares of Aquestive Therapeutics? Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AQST) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.